Bharat Biotech’s intranasal vaccine – Update

Bharat Biotech recently sought approval for its intranasal Covid vaccine candidate, BBV154, as two-dose vaccine as well as booster dose. It submitted data from Phase 3 clinical trials of BBV154 to seek approval.


  • The heterologous booster infers that, third or subsequent dose of the vaccine is not similar to its primary dose.
  • Usually, primary doses include two shots.
  • According to Bharat Biotech, BBV154 is stable at 2-8 degrees Celsius. It is safe, well-tolerated and immunogenic under controlled clinical trials.

About BBV154:

  • BBV154 is an intranasal vaccine, that have capability to produce local antibodies in upper respiratory tract. These are capable of reducing infection and transmission.
  • To evaluate BBV154 as primary dose and booster dose, two separate & simultaneous clinical trials were conducted.
  • Primary dose Phase III trials were conducted on more than 3000 individuals, to test its safety, and immunogenicity. Trials were conducted across 14 sites in India.
  • On the other hand, studies on heterologous booster dose were conducted on over 800 individuals.
  • This vaccine has been formulated to allow its delivery through nasal.
  • Nasal delivery system is cost-effective for low and middle-income countries.
  • BBV154 nasal vaccine has been developed by Bharat Biotech, in association with the Washington University.

Bharat Biotech International Limited (BBIL):

BBIL is headquartered in Hyderabad. The company is engaged in discovering drug, developing drug, manufacturing vaccines, pharmaceuticals and health care products. It was established in 1996.



Leave a Reply